Literature DB >> 2561156

A Chinese traditional medicine, juzentaihoto, inhibits the O2- generation by macrophages.

T Imamichi1, K Hayashi, T Nakamura, K Kaneko, J Koyama.   

Abstract

Guinea pig peritoneal macrophages generate superoxide anion (O2-), when stimulated with N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP), phorbol-myristate acetate (PMA) or ovalbumin complex of guinea pig IgG2 antibody (OA gamma 2). These responses were found to be inhibited by a Chinese traditional medicine, Juzentaihoto (JT). When the inhibition was assayed by the use of fMLP as a stimulant, at least one of the substances responsible for the inhibitory activity of JT was identified to be cinnamic acid. An authentic sample of cinnamic acid also inhibited the O2- generation by fMLP-stimulated macrophages. Cinnamic acid, however, did not inhibit the O2- generation, when macrophages were stimulated with PMA and OA gamma 2. These results indicate that a certain cinnamic acid-inhibitable factor may be involved in the intracellular triggering event(s) initiated by fMLP, leading to activation of the respiratory burst reduced nicotinamide adenine dinucleotide phosphate oxidase, but not in those by PMA and OA gamma 2.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2561156     DOI: 10.1248/bpb1978.12.693

Source DB:  PubMed          Journal:  J Pharmacobiodyn        ISSN: 0386-846X


  2 in total

1.  Protective effect of Juzen-taiho-to on hepatocarcinogenesis is mediated through the inhibition of Kupffer cell-induced oxidative stress.

Authors:  Masato Tsuchiya; Hiroshi Kono; Masanori Matsuda; Hideki Fujii; Ivan Rusyn
Journal:  Int J Cancer       Date:  2008-12-01       Impact factor: 7.396

2.  Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine.

Authors:  Shigeru Yutani; Nobukazu Komatsu; Satoko Matsueda; Munehiro Yoshitomi; Takahisa Shirahama; Akira Yamada; Kyogo Itoh; Tetsuro Sasada
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-10       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.